Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

CPRX – Catalyst Pharmaceuticals, Inc.

Float Short %

7.15

Margin Of Safety %

26

Put/Call OI Ratio

0.19

EPS Next Q Diff

-0.05

EPS Last/This Y

1.12

EPS This/Next Y

0.08

Price

22.73

Target Price

34.86

Analyst Recom

1.14

Performance Q

9.13

Relative Volume

1.08

Beta

0.73

Ticker: CPRX




19 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2025-12-09CPRX22.551.120.849184
2025-12-10CPRX22.81.1215.149256
2025-12-11CPRX22.931.170.199471
2025-12-12CPRX23.621.160.149495
2025-12-15CPRX24.181.140.299632
2025-12-16CPRX24.21.110.219820
2025-12-17CPRX24.011.130.759778
2025-12-18CPRX23.681.160.479658
2025-12-19CPRX23.741.174.969576
2025-12-22CPRX24.320.230.051742
2025-12-23CPRX24.240.170.012628
2025-12-26CPRX24.340.090.344835
2025-12-29CPRX24.050.090.144928
2025-12-30CPRX23.280.100.235459
2025-12-31CPRX23.320.110.065842
2026-01-02CPRX23.160.114.876186
2026-01-05CPRX22.810.190.656666
2026-01-06CPRX22.580.190.326686
2026-01-07CPRX22.730.190.526725
DateSymbolLatestP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-12-09CPRX22.55-33.828.12.50
2025-12-10CPRX22.55-33.843.02.50
2025-12-11CPRX22.94-33.840.82.50
2025-12-12CPRX23.61-33.850.22.50
2025-12-15CPRX24.18-33.848.02.50
2025-12-16CPRX24.18-33.838.52.50
2025-12-17CPRX24.00-33.835.52.50
2025-12-18CPRX23.67-33.833.32.50
2025-12-19CPRX23.75-33.840.02.50
2025-12-22CPRX24.28-33.847.52.50
2025-12-23CPRX24.19-33.836.72.50
2025-12-26CPRX24.35-33.837.12.50
2025-12-29CPRX24.05-33.833.92.50
2025-12-30CPRX23.28-33.826.22.50
2025-12-31CPRX23.32-33.839.22.50
2026-01-02CPRX23.15-33.835.42.50
2026-01-05CPRX22.81-33.832.82.50
2026-01-06CPRX22.58-33.834.92.50
2026-01-07CPRX22.73-33.841.32.50
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-12-09CPRX-3.661.607.66
2025-12-10CPRX-3.661.607.16
2025-12-11CPRX-2.101.607.16
2025-12-12CPRX-2.101.607.16
2025-12-15CPRX-2.061.777.16
2025-12-16CPRX-2.291.777.19
2025-12-17CPRX-2.211.777.19
2025-12-18CPRX-2.211.777.19
2025-12-19CPRX-2.211.777.19
2025-12-22CPRX-2.211.727.19
2025-12-23CPRX-2.211.727.19
2025-12-26CPRX-2.211.727.15
2025-12-29CPRX-2.211.717.15
2025-12-30CPRX-2.211.717.15
2025-12-31CPRX-2.211.717.15
2026-01-02CPRX-2.211.717.15
2026-01-05CPRX-2.211.577.15
2026-01-06CPRX-2.201.577.15
2026-01-07CPRX-2.201.577.15
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS

0.64

Avg. EPS Est. Current Quarter

0.46

Avg. EPS Est. Next Quarter

0.59

Insider Transactions

-2.2

Institutional Transactions

1.57

Beta

0.73

Average Sales Estimate Current Quarter

141

Average Sales Estimate Next Quarter

142

Fair Value

28.66

Quality Score

92

Growth Score

99

Sentiment Score

38

Actual DrawDown %

14.5

Max Drawdown 5-Year %

-45.4

Target Price

34.86

P/E

13.26

Forward P/E

12.97

PEG

1.06

P/S

4.83

P/B

3.04

P/Free Cash Flow

11.91

EPS

1.71

Average EPS Est. Cur. Y​

2.5

EPS Next Y. (Est.)

2.58

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

37.63

Relative Volume

1.08

Return on Equity vs Sector %

-3.4

Return on Equity vs Industry %

11.7

EPS 1 7Days Diff

0.2

EPS 1 30Days Diff

0.16

EBIT Estimation

41.3
Catalyst Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 181
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizures; Ruzurgi for the treatment of pediatric LEMS patients; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
stock quote shares CPRX – Catalyst Pharmaceuticals, Inc. Stock Price stock today
news today CPRX – Catalyst Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch CPRX – Catalyst Pharmaceuticals, Inc. yahoo finance google finance
stock history CPRX – Catalyst Pharmaceuticals, Inc. invest stock market
stock prices CPRX premarket after hours
ticker CPRX fair value insiders trading